References
- Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865–9
- Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, et al. European best practice guidelines 9-13: anaemia management. Nephrol Dial Transplant 2000; 15(Suppl 4)33–42
- Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578–83
- Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439–46
- Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607–14
- Fullerton, L, Bhattacharjee, D, Roe, SD, Cassidy, MJD. Erythropoietin: subcutaneous or intravenous dosing?. Br J Renal Med 2002/2003;7:17–9.
- Pussel BA, Walker R. Optimal doses of epoetin alfa for hemodialysis patients before and after switch from subcutaneous to intravenous administration. J Am Soc Nephrol 2003; 14: 268A
- De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 1998; 13: 1770–5
- Jacobs C, Macdougall IC, Horl WH. The effect of the route of administration (intravenous versus subcutaneous) on epoetin dose and hemoglobin concentration in hemodialysis patients. J Am Soc Nephrol 2003; 14: 769A
- Virot JS, Janin G, Guillaumie J, Michel P, Dubot P, Chevet D, et al. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?. Am J Kidney Dis 1996; 28: 400–8
- Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(Suppl 7)25–8
- Kooistra MP, van Es A, Struyvenberg A, Marx JJ. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991; 79: 634–9
- Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000; 15: 2014–9
- Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available preparations?. Nephrol Dial Transplant 2002; 17: 2047–51